RIST4721 for Hidradenitis Suppurativa

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Hidradenitis Suppurativa+1 More
RIST4721 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is studying RIST4721 to see if it is effective and safe in treating hidradenitis suppurativa.

Eligible Conditions
  • Hidradenitis Suppurativa

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Hidradenitis Suppurativa

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: Baseline to Week 12

Baseline to Week 12
Incidence of TEAEs and SAEs
Proportion of subjects achieving HiSCR50 at Week 12

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Other trials for Hidradenitis Suppurativa

Side Effects for

RIST4721 300 mg
33%Diarrhoea
20%Urine odour abnormal
13%Abnormal faeces
13%Folliculitis
13%Nausea
13%Musculoskeletal stiffness
13%Neutropenia
13%Procedural pain
7%Cough
7%Bacterial test
7%Headache
7%Osteoarthritis
7%Abdominal pain
7%Increased appetite
7%Pain in extremity
7%Decreased appetite
7%Fatigue
7%Anxiety
7%Blood glucose increased
7%Blood triglycerides increased
7%Hepatic enzyme increased
7%Concussion
7%Skin fissures
7%Leukopenia
7%Post procedural cellulitis
This histogram enumerates side effects from a completed 2019 Phase 2 trial (NCT03988335) in the RIST4721 300 mg ARM group. Side effects include: Diarrhoea with 33%, Urine odour abnormal with 20%, Abnormal faeces with 13%, Folliculitis with 13%, Nausea with 13%.

Trial Design

2 Treatment Groups

RIST4721 400 mg
1 of 2
Placebo
1 of 2
Experimental Treatment
Non-Treatment Group

33 Total Participants · 2 Treatment Groups

Primary Treatment: RIST4721 · Has Placebo Group · Phase 2

RIST4721 400 mg
Drug
Experimental Group · 1 Intervention: RIST4721 · Intervention Types: Drug
Placebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
RIST4721
2019
Completed Phase 2
~70

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline to week 12

Who is running the clinical trial?

Aristea Therapeutics, Inc.Lead Sponsor
5 Previous Clinical Trials
249 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have had a diagnosis of HS for at least 1 year.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 25th, 2021

Last Reviewed: October 13th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.